AU Patent

AU2013323669B2 — Insulin analog dimers

Assigned to Indiana University Research and Technology Corp · Expires 2018-03-01 · 8y expired

What this patent protects

Disclosed herein are insulin analog dimers having unique insulin receptor agonist activity based on insulin polypeptide sequences, the site of dimerization and the length of the dimerization linker that connects the two insulin polypeptides. In accordance with one embodiment the …

USPTO Abstract

Disclosed herein are insulin analog dimers having unique insulin receptor agonist activity based on insulin polypeptide sequences, the site of dimerization and the length of the dimerization linker that connects the two insulin polypeptides. In accordance with one embodiment the first and second insulin polypeptide are independently a two chain insulin analog or a single chain analog and the first and second insulin polypeptides are linked to one another via a B29-B29', B1-C8, B1-B1 or C8-C8 linkage.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013323669B2
Jurisdiction
AU
Classification
—
Expires
2018-03-01
Drug substance claim
No
Drug product claim
No
Assignee
Indiana University Research and Technology Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.